£80m To Tackle Snakebite Is A Wellcome Boost
Executive Summary
Two major initiatives have been announced which hope to revolutionize the treatment of snakebites, which claims the lives of up to 138,000 people a year.
You may also be interested in...
Pfizer And AbbVie JAKs Finally Join Dupixent In US Atopic Dermatitis Space
The arrival on the US eczema market of a couple of oral JAK inhibitors with stellar data on itching could provide a challenge to Sanofi and Regeneron's blockbuster Dupixent. However, Pfizer and AbbVie will have to overcome dermatologists' fears about the class-effect safety warnings their drugs come with.
France's Abivax Looks A Likely M&A Target
With a candidate for ulcerative colitis set to go into Phase III soon with a safety profile that looks cleaner than anti-TNFs and the JAK class, the French biotech could soon be getting some interesting offers.
Bayer Pharma R&D Head Tackles Challenge Of Prioritizing Promising Assets
Nearly a year into the job, research chief Christian Rommel tells Scrip he is impressed with Bayer's arm's length approach to running acquired firms like AskBio and BlueRock and the task ahead is to deliver on the potential they offer, while getting later-stage projects across the approvals finishing line.